Magazine Article | January 1, 2017

Companies To Watch: Ritter Pharmaceuticals

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

On a mission to develop the first FDA-approved, durable-efficacy therapeutic for lactose intolerance

SNAPSHOT
Cofounded by its namesake, Andrew Ritter, Ritter Pharmaceuticals is developing a treatment — not merely a symptom reliever — for lactose intolerance, which has plagued Ritter himself since childhood. It is entering Phase 3 development with a “gut-microbiome modifier” targeted at the condition, and it is in preclinical testing exploring microbiome-based treatments for metabolic syndrome, liver disease, cancer, and other gastrointestinal conditions.

THIS CONTENT IS EXCLUSIVELY FOR LIFE SCIENCE LEADER PAID SUBSCRIBERS.
To continue reading this story and receive uninterrupted access to LSL Online and its monthly magazine subscribe to Life Science Leader today!
Already a subscriber? Log in now.